Bioventus extends term loan maturity to 2030 to fund expansion
AI Summary- Bioventus is using cash from established orthopedic products to reduce debt and fund expansion.
- Bioventus extended its term loan maturity to 2030 and reduced its interest margin.
- The company is directing financing improvements toward debt reduction and commercial expansion.